Pharma BD Deal Intelligence
Franchise-adjacent, de-risked oral EGFR asset with 1L expansion upside
Full analysis, sources & comparables →AstraZeneca entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for lung cancer. AstraZeneca acquires worldwide rights to develop and commercialize the drug, paying Dizal $600M upfront plus up to $900M in development, regulatory and sales milestones and tiered royalties on global sales. Zegfrovy is already approved in China and the U.S. for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations after platinum-based chemotherapy; Dizal recently reported first-line Phase III WU-KONG28 results at ASCO 2026 (published in NEJM). The transaction is expected to close in H2 2026, subject to customary conditions and regulatory clearances.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd (this deal) | 2026 | $1.5B | 73 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2026 deals · AstraZeneca PLC deals · Oncology deals